Q3 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius Stedim Biotech SA (SDMHF) confirmed its guidance for the full year 2024, indicating confidence in meeting its financial targets.
- The company reported a significant increase in order intake, particularly driven by consumables, reflecting a positive trend in recurring business.
- Efficiency programs are positively impacting profitability, with expectations of further contributions in Q4.
- The EMEA region showed strong performance with approximately 5% growth, indicating regional strength.
- Cash flow significantly increased due to effective working capital and CapEx management, showcasing financial discipline.
- Sales revenue for the first 9 months of 2024 was slightly negative compared to the prior year, indicating challenges in achieving growth.
- The equipment business remains soft, with ongoing reluctance from customers to invest, particularly impacting the Bioprocess Solutions division.
- The Asia region, especially China, continues to underperform due to market corrections and local competition.
- Underlying EBITDA margin saw a slight decline due to mix effects and lower production volumes.
- The company faces challenges in the U.S. market due to overcapacity and destocking effects from the pandemic.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the 9 months 2024 Results. I am Serge, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead, sir.
Yes. Thank you very much. Welcome, everyone. Good day, and a pleasure to walk you through our results for the first 9 months of 2024. As always, we will do this together. That means it's myself and Florian Funck, CFO of the Sartorius Group as well as René Fáber, CEO of Sartorius Stedim Biotech, and we will start with the results of Sartorius AG or the Sartorius Group, and then thereafter we will walk you through the additional information on Sartorius Stedim Biotech.
So let me start with highlighting the key results of the first 9 months of 2024. And I think the 2 main points here are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
